EU Generic Industry Group Looks At Radical Options To Simplify Pharmacovigilance Tasks
Executive Summary
From looking at ways to reduce the number of audits undertaken by companies to fulfil their pharmacovigilance obligations to calling for harmonized assessment of risk management plans, the EU generics and biosimilars industry group Medicines for Europe says it is ready to explore some radical proposals to simplify the current pharmacovigilance requirements.
You may also be interested in...
EMA To Address Industry Concerns in Revised Signal Management Guideline
The European Medicines Agency is examining the “constructive and pragmatic” feedback it has received on its revised guideline on safety signal detection, which aims to help companies fulfil their new legal obligation to monitor EudraVigilance data and report validated signals within strict timelines.
EMA Revises Guidance On Risk Management Plans To Address Industry ‘Misunderstandings’
The European Medicines Agency is finalizing changes to its eagerly-awaited guidance on risk management plans, which aims to simplify the submission and maintenance of RMPs by drug companies. The EMA has fine-tuned the document to address some misunderstandings within the industry and is currently deciding on the transition plans for implementing the new requirements.
Roadmap On Improvements To EMA's Literature Monitoring Service Due By Year End
The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.